Raúl Márquez, Head of Gynecologic Oncology Unit at MD Anderson Cancer Center Madrid, shared on LinkedIn:
“Pleased to share our new publication in Gynecologic Oncology from the OPAL-C phase 2 trial.
In newly diagnosed HRD advanced ovarian cancer, neoadjuvant niraparib did not outperform platinum-taxane chemotherapy: ORR was 31.6% vs 70.6%, respectively, and the trial was stopped early for futility. Results should be interpreted cautiously, given the limitations of the study.
An important reminder that biological rationale must ultimately be validated by clinical evidence.
Proud to have contributed to this international collaboration.”
Title: Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial
Authors: Shannon N. Westin, Jimmy Belotte, Brunella Felicetti, Vishvajit Aghera, Ahmed YoussefAgha, Evi Bakirtzi, Ana Godoy Ortiz, Arantzazu Barquín García, Diane Provencher, Raúl Márquez Vázquez, Lucia González Cortijo, Xing Zeng, Dan-Arin Silasi, Leslie S. Bradford, Fernanda B. Musa, John K. Chan, Joyce F. Liu, Luis Rojas-Espaillat
You can also read: Carboplatin: A Key Platinum Chemotherapy in Cancer Treatment
